Mapping blood vessel characteristics in brain tumors
Official title: Vascular Signature Mapping of Brain Tumor Genotypes
Run by Leiden University Medical Center · NCT05274919 · Data updated 2026-11-12
This study is testing a new MRI technique to see if it can help doctors understand the blood vessels in brain tumors without needing to do a biopsy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Leiden University Medical Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Leiden and 1 other locations) |
| Status | Recruiting |
| Started | August 16, 2022 |
| Main results expected | March 31, 2026 |
| Study ends | March 31, 2026 |
| Registry record updated | March 10, 2025 |
| Trial ID | NCT05274919 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who are scheduled for brain MRI with contrast injection due to suspected glioma.
✕Probably not a fit
Patients with contraindications for MRI, reduced kidney function, or those who are pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop and validate a fast MRI technique to non-invasively characterize the vascularization of gliomas, a type of brain tumor. By utilizing advanced MRI protocols at 3T and 7T, the researchers will gather quantitative data on tumor vascular properties. Additionally, a computer-aided diagnostic algorithm will be created to predict tumor genotypes based on the vascular signature maps obtained from the MRI scans. This approach seeks to reduce the need for invasive tissue biopsies by providing insights into the tumor's biological behavior through imaging.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for determining the biological behavior of gliomas, potentially improving treatment timing and outcomes for patients.
How similar studies have gone: While the approach of using MRI for tumor characterization is established, this specific method of vascular signature mapping is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients scheduled for brain MRI with contrast injection as part of the clinical diagnostic procedure (cohort 1) * Patients diagnosed with suspected glioma scheduled for brain MRI as part of the clinical diagnostic procedure (cohort 2) * Patients with (suspected) glioma referred for tumor biopsy or resection (cohort 3) * Age ≥ 18 years (all cohorts) * Signed informed consent (all cohorts) Exclusion Criteria: * Subjects with contra-indications for an MRI exam * Subjects with reduced kidney function because of the risk on developing nephrogenic systemic fibrosis (NSF) under gadolinium-based contrast injection * Subjects with pregnancy * Subjects undergoing a clinical protocol that requires scanning during CA injection (cohort 1)
Where it's running
-
Erasmus University Medical Center
Rotterdam, Netherlands Recruiting -
Leiden University Medical Center
Leiden, Netherlands Not yet recruiting
Study contacts
- Principal investigator: Matthias JP van Osch, Prof Dr Ir — Leiden University Medical Center
- Study coordinator: Daniëlle van Dorth, MSc
- Email: D.van_Dorth@lumc.nl
- Phone: +31657056608
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.